PCRX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Pacira Biosciences Inc (PCRX) is not a strong buy for a beginner, long-term investor at this moment. While the company has potential in the specialty pharmaceuticals sector, its recent financial performance, insider selling, and below-consensus revenue projections for 2026 suggest caution. Additionally, technical indicators and options sentiment do not strongly support a bullish outlook.
The MACD is positive but contracting, RSI is neutral at 48.049, and moving averages are converging, indicating no strong trend. The stock is trading near its pivot level of 22.605, with key support at 21.673 and resistance at 23.537.
Hedge funds have significantly increased their buying activity, up 695.83% last quarter. The company aims to assist 3 million patients by 2030 and has extended EXPAREL's patent protection through 2039.
Insiders have increased selling by 928.27% in the last month. The company's Q4 2025 EPS dropped significantly by 88.57% YoY, and its 2026 revenue projection is below market consensus. Options sentiment is bearish, and the stock has a 60% chance of declining in the next week and month.
In Q4 2025, revenue increased by 5.14% YoY, but net income dropped by 89.79% YoY, and EPS fell by 88.57% YoY. Gross margin improved slightly to 72.26%. Overall, the financial performance shows growth in revenue but significant declines in profitability.
Barclays initiated coverage with an Equal Weight rating and a $27 price target, indicating a neutral stance. The specialty pharmaceuticals sector is seen as having opportunities but remains in a transition phase.
